{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:36:26Z","timestamp":1790422586597,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"20","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2021,10,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The efficacy and safety of transarterial chemoembolization (TACE) plus lenvatinib in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) have not been evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>In this open\u2010label, single\u2010center, randomized trial (ClinicalTrials.gov identifier: NCT04127396), participants with previously untreated HCC and type I\u2010IV PVTT were randomized 1:1 to receive TACE plus lenvatinib (arm L; orally once daily, 12 mg for body weight \u226560 kg or 8 mg for body weight &lt;60 kg) or TACE plus sorafenib (arm S; 400 mg orally twice daily in 28\u2010day cycles). The primary end point was time\u2010to\u2010progression (TTP; time from randomization to disease progression) and secondary end points included objective response rate and toxicity. Prognostic factors were evaluated using a multivariable Cox proportional hazards model.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Between December 30, 2018 and May 31, 2020, 64 patients were randomized (arm L, n = 32; arm S, n = 32); most patients had type I\/II PVTT (71.9%), and the median target tumor diameter was 9.8 cm (range, 3.8\u201021.8). After a median follow\u2010up of 16.1 months, patients in arm L had a higher median TTP (4.7 vs 3.1 months; hazard ratio [HR], 0.55; 95% CI, 0.32\u20100.95; <jats:italic>P<\/jats:italic> = .029) and objective response rate (53.1% vs 25.0%, <jats:italic>P<\/jats:italic> = .039) versus arm S. Multivariable analysis showed that TACE plus lenvatinib was significantly associated with higher TTP versus TACE plus sorafenib (HR, 0.50; 95% CI, 0.28\u20100.90; <jats:italic>P<\/jats:italic> = .021). Comparable safety profiles were observed in arms L and S.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>TACE plus lenvatinib was safe, well tolerated, and had favorable efficacy versus TACE plus sorafenib in patients with advanced HCC with PVTT and large tumor burden.<\/jats:p><\/jats:sec><jats:sec><jats:title>LAY SUMMARY<\/jats:title><jats:p>\n<jats:list list-type=\"bullet\">\n\n<jats:list-item><jats:p>Hepatocellular carcinoma with portal vein tumor thrombus has a poor prognosis.<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>In addition, most phase 3 trials of drugs for hepatocellular carcinoma exclude patients with major portal vein invasion, and treatment options for these patients are limited.<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Transarterial chemoembolization has shown promising efficacy in these patients, especially in combination with systemic treatment or radiotherapy. However, transarterial chemoembolization plus lenvatinib has not been investigated in this setting.<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>This open\u2010label, single\u2010center, randomized trial showed that transarterial chemoembolization plus lenvatinib is safe, well tolerated, and has favorable efficacy versus transarterial chemoembolization plus sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombus.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.33677","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T13:56:09Z","timestamp":1625752569000},"page":"3782-3793","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first\u2010line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study"],"prefix":"10.1002","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5787-4401","authenticated-orcid":false,"given":"Xiaoyan","family":"Ding","sequence":"first","affiliation":[{"name":"Department of Cancer Center Beijing Ditan Hospital Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Cancer Center Beijing Ditan Hospital Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cancer Center Beijing Ditan Hospital Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Cancer Center Beijing Ditan Hospital Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodi","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cancer Center Beijing Ditan Hospital Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Cancer Center Beijing Ditan Hospital Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cancer Center Beijing Ditan Hospital Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Jinan Eco\u2010environmental Monitoring Center of Shandong Province Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cancer Center Beijing Ditan Hospital Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cancer Center Beijing Ditan Hospital Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2018.06.01"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503685"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199808000-00014"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318934"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.03.042"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.13130150"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2014.10.019"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.11.029"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2017.04.016"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051116"},{"key":"e_1_2_9_16_1","first-page":"112","article-title":"Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)","volume":"28","author":"Department of Medical Administration, National Health and Health Commission of the People's Republic of China","year":"2020","journal-title":"Chinese J Hepatol"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.012"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2018171541"},{"key":"e_1_2_9_19_1","unstructured":"National Cancer Institute.Common Terminology Criteria for Adverse Events v4.0 (CTCAE).2009. Accessed June 14 2010.http:\/\/ctep.cancer.gov\/forms\/CTCAEv4.0pdf"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0196"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.578633"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29086"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy308"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15075"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14193"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30011-5"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12207"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12266"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2017.10.018"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000489790"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000502095"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070952"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2020.03.002"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.33677","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.33677","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.33677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:36:44Z","timestamp":1760301404000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.33677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":34,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,10,15]]}},"alternative-id":["10.1002\/cncr.33677"],"URL":"https:\/\/doi.org\/10.1002\/cncr.33677","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"assertion":[{"value":"2021-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}